Therap adv gastroenterol影响因子
_中科院分区_SCI期刊投稿经 …)
Webb期刊名： ADVANCES IN THERAPY 期刊名缩写： ADV THER 期刊ISSN： 0741-238X E-ISSN： 1865-8652 2024年影响因子/JCR分区： 4.070/Q2 学科与分区： PHARMACOLOGY & PHARMACY - SCIE (Q2); MEDICINE, RESEARCH & EXPERIMENTAL - SCIE (Q3) 出版国家或地区： ENGLAND 出版周期： Monthly 出版年份： 1984 年文章数： 194 是否OA开放访 … WebbSecond Near‐Infrared Light Triggered Mini Plasmonic Heterostructures for Photothermal‐Derived Multimodal Synergistic Cancer Therapy. Zhourui Xu, Ravikumar … Depression is one of the most prevalent mental diseases. The physiological and … Click on the title to browse this list of Accepted articles. These are the … Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle … Christine Mayer: Chris received her PhD in microbiology from the University … This study investigates the immunomodulatory effect (targeting … Editorial Board. Our journal is managed by professional in-house editors who handle … If the address matches an existing account you will receive an email with instructions … Hailing Zhang. Department of Neurology, Changhai Hospital, Naval Medical …
Therap adv gastroenterol影响因子
Did you know?
WebbScope. Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly … WebbCenter for Advanced Studies and Technology (CAST), ‘G. d’Annunzio’ University of Chieti-Pescara, Chieti, Italy Matteo Neri Department of Medicine and Ageing Sciences, ‘G. …
WebbThe scope of this journal includes pathology, diagnosis, and treatment of diseases of the gastrointestinal tract, liver, pancreas, gall bladder, and biliary tract, such as functional … Webb27 maj 2024 · The impact score (IS) 2024 of Therapeutic Advances in Gastroenterology is 4.52, which is computed in 2024 as per its definition. Therapeutic Advances in …
Webb期刊名称. THER ADV GASTROENTER/Therapeutic Advances in Gastroenterology. ISSN. 1756-283X. 影响指数话题. 影响指数话题. 预警等级. MedSci期刊指数. 10.433 （MedSci …
Webb23 dec. 2024 · Tofacitinib is a safe and effective therapy in real-world UC patients, as previously reported by clinical trials. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis Therap Adv Gastroenterol. 2024 Dec 23;14:17562848211064004.doi: 10.1177/17562848211064004. eCollection 2024. Authors
http://www.yueqikan.com/s/202410319348.html early head start rockford ilWebbTherapeutic Advances in Gastroenterology杂志网站提供THER ADV GASTROENTER期刊影响因子、JCR和中科院分区查询，SCI期刊投稿经验，Impact Factor ... cstimer color schemesWebb影响因子 Clinical Gastroenterology and Hepatology，近年来影响因子增长，今年预测为11.382，发展潜力大 后台扫描，可以查看更多期刊信息 从官网统计的数据来看，2024 … cst ifa天线仿真WebbJ Gastroenterol. 2024;53(3): 354 – 361. , , [Web of Science ®], [Google Scholar] Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2024;12: 1756284819858511. cs timer.comWebb10 dec. 2024 · Year 2024. PubMed DOI Crossref. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective … cstimer bluetoothWebb27 maj 2024 · The impact score (IS) 2024 of Clinical and Experimental Gastroenterology is 2.84, which is computed in 2024 as per its definition.Clinical and Experimental Gastroenterology IS is decreased by a factor of 0.69 and approximate percentage change is -19.55% when compared to preceding year 2024, which shows a falling trend. The … c. s. timerWebbissn： 1756-2848: 缩写名： ther adv gastroenter: 2024影响因子： 3.961: 中科院分区(2024)： 2 区: 大类学科： 医学: 小类学科： 年文章数： cstimer account